Pharma Mar SA

PHM

Equity

ISIN ES0169501022 / Valor 56130572

BME Bolsas y Mercados Espanoles - Renta Variable (2025-04-04)

EUR 75.50-3.02%

Pharma Mar SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Pharma Mar SA, headquartered in Madrid, Spain, is a biopharmaceutical company specializing in the development of oncology drugs derived from marine biodiversity. Established in 1986, the company has a strong focus on researching and developing treatments for rare cancers, leveraging the unique antitumor properties found in marine organisms. Pharma Mar commercializes three main drugs, which, through partnerships with 18 companies, are distributed in over 70 countries. The company has a significant international presence with subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the United States. Pharma Mar is committed to reinvesting its profits and partner revenues into research and development, as well as the continuous training of its team, to advance its mission of providing innovative cancer therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Pharma Mar SA reported a group revenue of €126.5 million for the first nine months of 2024, marking an 8% increase compared to the same period in 2023. This growth was driven by both recurring and non-recurring revenue streams, with recurring revenue, including net sales and royalties, reaching €99.2 million, a slight increase from the previous year.

Oncology Segment Performance

The oncology segment of Pharma Mar SA saw a net revenue of €57.0 million in the first nine months of 2024, which is a 4% decrease from the same period in 2023. This decline was primarily due to reduced sales of Yondelis in the European market, although sales of raw materials to partners increased significantly, reflecting preparations for commercial sales.

Royalties and Non-Recurring Revenue

Royalties revenue for Pharma Mar SA increased by 10% to €42.2 million in the first nine months of 2024, with significant contributions from Zepzelca sales by Jazz Pharmaceuticals. Non-recurring revenue, mainly from out-licensing agreements, also saw a substantial increase, amounting to €26.9 million compared to €18.9 million in the same period of 2023.

EBITDA and Net Profit

Pharma Mar SA's EBITDA for the first nine months of 2024 was €6.3 million, a 14% increase from the previous year. However, the net profit for the period was slightly lower at €7.4 million compared to €7.9 million in 2023, influenced by a positive financial result and income tax effects.

Cash Position and Debt

As of September 30th, 2024, Pharma Mar SA had a positive net cash position of €97.3 million, despite a reduction from the previous year-end due to investments in the oligonucleotide production plant. The company also arranged a €15.0 million bank loan to finance this new facility, contributing to an increase in total interest-bearing debt.

Summarized from source with an LLMView Source

Key figures

166%1Y

2.14%3Y

36.5%5Y

Performance

46.0%1Y

40.1%3Y

52.6%5Y

Volatility